Patents by Inventor Mark S. Lent

Mark S. Lent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9724511
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 8, 2017
    Assignee: Medtronic, Inc.
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Patent number: 9597154
    Abstract: A method and apparatus for optimizing a computer assisted procedure is provided. A method and apparatus for performing a procedure is also provided. Data can be accessed and processed to optimize and perform a procedure. The data can be augmented or supplemented with patient specific data.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 21, 2017
    Assignee: Medtronic, Inc.
    Inventors: David A. Simon, Mark S. Lent, Ruchika Singhal, Andrew N. Csavoy
  • Publication number: 20160367803
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Patent number: 9433783
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 6, 2016
    Assignee: Medtronic, Inc.
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Publication number: 20160030741
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Patent number: 9155885
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 13, 2015
    Assignee: Medtronic, Inc.
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Publication number: 20140350636
    Abstract: Peripheral nerve field stimulation (PNFS) may be controlled based on detected physiological effects of the PNFS, which may be an efferent response to the PNFS. In some examples, a closed-loop therapy system may include a sensing module that senses a physiological parameter of the patient, which may be indicative of the patient's response to the PNFS. Based on a signal generated by the sensing module, the PNFS may be activated, deactivated or modified. Example physiological parameters of the patient include heart rate, respiratory rate, electrodermal activity, muscle activity, blood flow rate, sweat gland activity, pilomotor reflex, or thermal activity of the patient's body. In some examples, a patient pain state may be detected based on a signal generated by the sensing module, and therapy may be controlled based on the detection of the pain state.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Gary W. King, Steven M. Goetz, Andrew H. Houchins, Jeffrey T. Keacher, Jordan J. Greenberg, Kenneth T. Heruth, Mark S. Lent, Paul W. Wacnik
  • Patent number: 8805518
    Abstract: Peripheral nerve field stimulation (PNFS) may be controlled based on detected physiological effects of the PNFS, which may be an efferent response to the PNFS. In some examples, a closed-loop therapy system may include a sensing module that senses a physiological parameter of the patient, which may be indicative of the patient's response to the PNFS. Based on a signal generated by the sensing module, the PNFS may be activated, deactivated or modified. Example physiological parameters of the patient include heart rate, respiratory rate, electrodermal activity, muscle activity, blood flow rate, sweat gland activity, pilomotor reflex, or thermal activity of the patient's body. In some examples, a patient pain state may be detected based on a signal generated by the sensing module, and therapy may be controlled based on the detection of the pain state.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 12, 2014
    Assignee: Medtronic, Inc.
    Inventors: Gary W. King, Steven M. Goetz, Andrew H. Houchins, Jeffrey T. Keacher, Jordan J. Greenberg, Kenneth T. Heruth, Mark S. Lent, Paul W. Wacnik
  • Publication number: 20140171791
    Abstract: A method and apparatus for optimizing a computer assisted procedure is provided. A method and apparatus for performing a procedure is also provided. Data can be accessed and processed to optimize and perform a procedure. The data can be augmented or supplemented with patient specific data.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: Medtronic, Inc.
    Inventors: David A. SIMON, Mark S. Lent, Ruchika Singhal, Andrew N. Csavoy
  • Patent number: 8691258
    Abstract: Implantable medical devices (IMDS) having anti-infective properties are described. Anti-infective agents are disposed in, on, or about at least a portion of a surface of the medical device. The anti-infective agents are disposed in or on a vehicle, which may be in the form of a coating layer or covering. The vehicle may be biodegradable so that, over time, the anti-infective agent is removed from a tissue location into which the device is implanted, reducing the likelihood that microorganisms resistant to the anti-infective agent will develop. IMDs having an anti-infective agent and an anti-activity agent disposed therein, thereabout, or thereon are also described. The anti-activity agent interferes with the activity of the anti-infective agent, may be released from a surface at the IMD at a time when activity of the anti-infective agent is no longer desired, and may reduce the likelihood that microorganisms resistant to the anti-infective agent will develop.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: April 8, 2014
    Assignee: Medtronic, Inc.
    Inventors: Kenneth T. Heruth, Christopher M. Hobot, William J. Hooper, Mark S. Lent, Ruchika Singhal, Robert M. Skime, Randall V. Sparer, Maura G. Donovan, William J. Bertrand
  • Patent number: 8666497
    Abstract: In an implantable medical device having individual modules, a coupling module couples the modules to one another. The coupling module supports electrical and/or mechanical coupling of the modules. The coupling module may assume a variety of shapes or configurations. The various embodiments of the coupling module may offer the modules varying degrees of freedom of movement relative to one another.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: March 4, 2014
    Assignee: Medtronic, Inc.
    Inventors: Darren A. Janzig, Carl D. Wahlstrand, Robert M. Skime, Mark S. Lent, Keith A. Miesel, James E. Cabak
  • Publication number: 20140058292
    Abstract: A system for use in managing a neuromodulation therapy includes an ultrasound transducer array controlled by a control unit to deliver ultrasound waveforms for causing modulation of neural tissue in a patient. The system acquires data indicating a response to the modulation, analyzes the acquired data to determine correlation data between a response to the modulation and an ultrasound control parameter, and reports the correlation data to enable identification of at least one therapy parameter to be used to deliver a neuromodulation therapy to the patient by a therapy delivery system.
    Type: Application
    Filed: January 24, 2013
    Publication date: February 27, 2014
    Applicant: Medtronic, Inc.
    Inventors: Jamu Alford, Steven M. Goetz, Lothar Krinke, Mark S. Lent, Erik R. Scott, Xuan K. Wei, John D. Welter
  • Patent number: 8660635
    Abstract: A method and apparatus for optimizing a computer assisted procedure is provided. A method and apparatus for performing a procedure is also provided. Data can be accessed and processed to optimize and perform a procedure. The data can be augmented or supplemented with patient specific data.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: February 25, 2014
    Assignee: Medtronic, Inc.
    Inventors: David Simon, Mark S. Lent, Ruchika Singhal, Andrew N. Csavoy
  • Patent number: 8554325
    Abstract: A movement state of a patient is detected based on brain signals, such as an electroencephalogram (EEG) signal. In some examples, a brain signal within a dorsal-lateral prefrontal cortex of a brain of the patient indicative of prospective movement of the patient may be sensed in order to detect the movement state. The movement state may include the brain state that indicates the patient is intending on initiating movement, initiating movement, attempting to initiate movement or is actually moving. In some examples, upon detecting the movement state, a movement disorder therapy is delivered to the patient. In some examples, the therapy delivery is deactivated upon detecting the patient is no longer in a movement state or that the patient has successfully initiated movement. In addition, in some examples, the movement state detected based on the brain signals may be confirmed based on a signal from a motion sensor.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: October 8, 2013
    Assignee: Medtronic, Inc.
    Inventors: Gregory F. Molnar, Steven S. Gill, Keith A. Miesel, Mark S. Lent, Timothy J. Denison, Eric J. Panken, Carl D. Wahlstrand, Jonathan C. Werder
  • Patent number: 8246602
    Abstract: Devices, systems and methods for delivering one or more drugs to one or more internal body locations (such as the cerebrospinal fluid) are disclosed. In various aspects, the systems and methods may involve catheters having infusion sections with permeable membranes and one or more tracking elements that may be used to place the infusions sections on the catheters in selected locations such as the spinal region.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: August 21, 2012
    Assignee: Medtronic, Inc.
    Inventors: Kenneth T. Heruth, Mark S. Lent, Justin A. Blanco
  • Patent number: 8244360
    Abstract: Systems and methods for coordinated delivery of a therapeutic agent and low (less than about 20 Hz) and high (greater than about 50 Hz) frequency stimulation therapy are described. The systems include a control unit for coordinating therapy delivery between an infusion device and a pulse generator, such that a therapeutic agent is administered at a predetermined time relative to application of either low frequency or high frequency stimulation. For example, the control unit may instruct the infusion device to deliver therapeutic agent at a predetermined time prior to delivery of low frequency stimulation. Systems that include more than one infusion device or an infusion pump capable of delivering more than one therapeutic agent are also described.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: August 14, 2012
    Assignee: Medtronic, Inc.
    Inventors: Kenneth T. Heruth, Mark S. Lent, Ruchika Singhal, Michael J. Schendel
  • Publication number: 20120203212
    Abstract: Devices, systems and methods for delivering one or more drugs to the cerebrospinal fluid periodically replace continuous infusion of the a solution with intermittent bolus infusion of the solution to reduce the local concentration of a drug over time at a vertebral level in the patient's spinal canal relative to the drug infused continuously through the infusion section of a catheter intrathecally into a patient's spinal canal at the vertebral level. Such periodic replacement of continuous infusion with intermittent bolus infusion assists in prevention formation of an inflammatory mass at the vertebral level.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 9, 2012
    Applicant: Medtronic, Inc.
    Inventors: Kenneth T. Heruth, Mark S. Lent
  • Patent number: 8216177
    Abstract: Devices, systems and methods for delivering one or more drugs to one or more internal body locations (such as the cerebrospinal fluid) are disclosed. In various aspects, the systems and methods may involve catheters having infusion sections with permeable membranes that develop significant back pressure to enhance uniform delivery of the drug over an infusion section; catheters that have two or more infusion sections spaced apart along the length of the same catheter, catheters that include two or more infusion sections serviced by independent lumens (such that, e.g., different drug solutions can be delivered to the different infusion sections); implantable drug delivery systems with pumps and multiple reservoirs from which drugs can be delivered; systems that are capable of delivering drug solutions with selected densities; etc.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: July 10, 2012
    Assignee: Medtronic, Inc.
    Inventors: Kenneth T Heruth, Mark S Lent, Justin A Blanco
  • Publication number: 20120130444
    Abstract: Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.
    Type: Application
    Filed: April 9, 2010
    Publication date: May 24, 2012
    Applicant: MEDTRONIC, INC.
    Inventors: Xuan K. Wei, Eric H. Bonde, Keith A. Miesel, Mark S. Lent, Gregory F. Molnar
  • Publication number: 20120108998
    Abstract: A movement state of a patient is detected based on brain signals, such as an electroencephalogram (EEG) signal. In some examples, a brain signal within a dorsal-lateral prefrontal cortex of a brain of the patient indicative of prospective movement of the patient may be sensed in order to detect the movement state. The movement state may include the brain state that indicates the patient is intending on initiating movement, initiating movement, attempting to initiate movement or is actually moving. In some examples, upon detecting the movement state, a movement disorder therapy is delivered to the patient. In some examples, the therapy delivery is deactivated upon detecting the patient is no longer in a movement state or that the patient has successfully initiated movement. In addition, in some examples, the movement state detected based on the brain signals may be confirmed based on a signal from a motion sensor.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Inventors: Gregory F. Molnar, Steven S. Gill, Keith A. Miesel, Mark S. Lent, Timothy J. Denison, Eric J. Panken, Carl D. Wahlstrand, Jonathan C. Werder